Nonlinear Mixed-effect Models for Prostate-specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: A Comparison by Simulation of Two-stage and Joint Approaches.
In metastatic castration-resistant prostate cancer (mCRPC) clinical trials, the assessment of treatment efficacy essentially relies on the time to death and the kinetics of prostate-specific antigen (PSA). Joint modeling has been increasingly used to characterize the relationship between a time to event and a biomarker kinetics, but numerical difficulties often limit this approach to linear models. Here, we evaluated by simulation the capability of a new feature of the Stochastic Approximation Expectation-Maximization algorithm in Monolix to estimate the parameters of a joint model where PSA kinetics was defined by a mechanistic nonlinear mixed-effect model. The design of the study and the parameter values were inspired from one arm of a clinical trial. Increasingly high levels of association between PSA and survival were considered, and results were compared with those found using two simplified alternatives to joint model, a two-stage and a joint sequential model. We found that joint model allowed for a precise estimation of all longitudinal and survival parameters. In particular, the effect of PSA kinetics on survival could be precisely estimated, regardless of the strength of the association. In contrast, both simplified approaches led to bias on longitudinal parameters, and two-stage model systematically underestimated the effect of PSA kinetics on survival. In summary, we showed that joint model can be used to characterize the relationship between a nonlinear kinetics and survival. This opens the way for the use of more complex and physiological models to improve treatment evaluation and prediction in oncology.
INSERM, IAME, UMR 1137, F-75018, Paris, France, solene.desmee@inserm.fr.
Solène
S
Desmée
France
F
Mentré
Christine
C
Veyrat-Follet
Jérémie
J
Guedj
D000465:Algorithms; D003198:Computer Simulation; D006801:Humans; D008297:Male; D008954:Models, Biological; D009362:Neoplasm Metastasis; D017711:Nonlinear Dynamics; D017430:Prostate-Specific Antigen / Q000378:metabolism*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000473:pathology* / Q000628:therapy; D013534:Survival; D013997:Time Factors; D016896:Treatment Outcome
D017430:Prostate-Specific Antigen